Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2124426rdf:typepubmed:Citationlld:pubmed
pubmed-article:2124426lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:2124426lifeskim:mentionsumls-concept:C0268790lld:lifeskim
pubmed-article:2124426lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:2124426lifeskim:mentionsumls-concept:C0005823lld:lifeskim
pubmed-article:2124426lifeskim:mentionsumls-concept:C0392756lld:lifeskim
pubmed-article:2124426lifeskim:mentionsumls-concept:C1157322lld:lifeskim
pubmed-article:2124426lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:2124426lifeskim:mentionsumls-concept:C0857121lld:lifeskim
pubmed-article:2124426pubmed:issue6 Pt 2lld:pubmed
pubmed-article:2124426pubmed:dateCreated1991-1-31lld:pubmed
pubmed-article:2124426pubmed:abstractTextTo assess the potential role of the lipoxygenase (LO) pathway in the vasculature in an angiotensin II (ANG II)-dependent model of hypertension, we investigated the effect of LO pathway inhibition on blood pressure in the two-kidney, one-clip (2K,1C) Goldblatt hypertensive rat. The development of renovascular hypertension in 2K,1C rats was attenuated by oral administration of phenidone (Phe, 60 mg.kg-1.day-1), a nonselective LO inhibitor, throughout the 3 wk of observation after renal artery constriction. In contrast, the same treatment protocol had no effect on the evolution of hypertension in the deoxycorticosterone acetate-salt rat, which is considered to be an ANG II-independent form of hypertension. The hypotensive effect of Phe was not associated with changes in plasma renin or aldosterone concentration (PRC and PAC, respectively). In vitro synthesis of 12-hydroxyeicosatetraenoic acid (12-HETE) by aortic segments was increased in 2K,1C hypertensive rats compared with sham-operated rats. In addition, the synthesis of 12-HETE was suppressed by the in vitro addition of Phe (10(-4) M) to aortic-segment incubates obtained from 2K,1C rats and sham-operated rats. Acute administration of Phe (30 or 60 mg/kg) in 2K,1C hypertensive rats produced a rapid and sustained decrease in mean blood pressure (MBP). This decrease in MBP was accompanied by a brisk rise in PRC and PAC. In contrast, bolus administration of indomethacin, a selective cyclooxygenase inhibitor, did not affect MBP, PRC, or PAC.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:2124426pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2124426pubmed:languageenglld:pubmed
pubmed-article:2124426pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2124426pubmed:citationSubsetIMlld:pubmed
pubmed-article:2124426pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2124426pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2124426pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2124426pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2124426pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2124426pubmed:statusMEDLINElld:pubmed
pubmed-article:2124426pubmed:monthDeclld:pubmed
pubmed-article:2124426pubmed:issn0002-9513lld:pubmed
pubmed-article:2124426pubmed:authorpubmed-author:EggenaPPlld:pubmed
pubmed-article:2124426pubmed:authorpubmed-author:TuckM LMLlld:pubmed
pubmed-article:2124426pubmed:authorpubmed-author:SternNNlld:pubmed
pubmed-article:2124426pubmed:authorpubmed-author:GolubMMlld:pubmed
pubmed-article:2124426pubmed:authorpubmed-author:NozawaKKlld:pubmed
pubmed-article:2124426pubmed:authorpubmed-author:NadlerJ LJLlld:pubmed
pubmed-article:2124426pubmed:issnTypePrintlld:pubmed
pubmed-article:2124426pubmed:volume259lld:pubmed
pubmed-article:2124426pubmed:ownerNLMlld:pubmed
pubmed-article:2124426pubmed:authorsCompleteYlld:pubmed
pubmed-article:2124426pubmed:paginationH1774-80lld:pubmed
pubmed-article:2124426pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:2124426pubmed:meshHeadingpubmed-meshheading:2124426-...lld:pubmed
pubmed-article:2124426pubmed:meshHeadingpubmed-meshheading:2124426-...lld:pubmed
pubmed-article:2124426pubmed:meshHeadingpubmed-meshheading:2124426-...lld:pubmed
pubmed-article:2124426pubmed:meshHeadingpubmed-meshheading:2124426-...lld:pubmed
pubmed-article:2124426pubmed:meshHeadingpubmed-meshheading:2124426-...lld:pubmed
pubmed-article:2124426pubmed:meshHeadingpubmed-meshheading:2124426-...lld:pubmed
pubmed-article:2124426pubmed:meshHeadingpubmed-meshheading:2124426-...lld:pubmed
pubmed-article:2124426pubmed:meshHeadingpubmed-meshheading:2124426-...lld:pubmed
pubmed-article:2124426pubmed:meshHeadingpubmed-meshheading:2124426-...lld:pubmed
pubmed-article:2124426pubmed:meshHeadingpubmed-meshheading:2124426-...lld:pubmed
pubmed-article:2124426pubmed:meshHeadingpubmed-meshheading:2124426-...lld:pubmed
pubmed-article:2124426pubmed:meshHeadingpubmed-meshheading:2124426-...lld:pubmed
pubmed-article:2124426pubmed:year1990lld:pubmed
pubmed-article:2124426pubmed:articleTitleInhibition of lipoxygenase pathway reduces blood pressure in renovascular hypertensive rats.lld:pubmed
pubmed-article:2124426pubmed:affiliationDivision of Endocrinology, Sepulveda Veterans Administration Medical Center, California.lld:pubmed
pubmed-article:2124426pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2124426pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:2124426pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
pubmed-article:2124426pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2124426lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2124426lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2124426lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2124426lld:pubmed